secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bionano Genomics, Inc. (BNGO)
CIK:        0001411690
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001411690-22-000028
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bionano Genomics reports Q3 2022 revenue of $7.2M, up 55% YoY; guides Q4 $7.5-8M
--------------------------------------------------------------------------------

- Revenue $7.2M, up 55% YoY and 8% sequentially; gross margin 25%, up 3% sequentially.
- Installed base of Saphyr systems increased to 217, up 11% sequentially and 54% YoY; record flowcell sales of 3,975.
- GAAP operating expense $34.0M; non-GAAP $26.4M; cash $180.2M.
- Q4 2022 revenue guidance $7.5M to $8M.
- Bionano Laboratories received CLIA certification; launched first OGM-based LDT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411690/000141169022000028/0001411690-22-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411690/000141169022000028/bngo-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001411690-22-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer